NASDAQ:VBIV - VBI Vaccines Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.53 +0.13 (+9.29 %) (As of 12/14/2018 04:00 PM ET)Previous Close$1.53Today's Range$1.40 - $1.5452-Week Range$1.30 - $4.70Volume1.29 million shsAverage Volume662,478 shsMarket Capitalization$90.14 millionP/E RatioN/ADividend YieldN/ABeta2.02 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the target virus. It is also developing congenital cytomegalovirus vaccine candidate for infectious disease; and therapeutic glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts. VBI Vaccines Inc. is a subsidiary of FDS Pharma ASS. Receive VBIV News and Ratings via Email Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBIV Previous Symbol CUSIPN/A Webwww.vbivaccines.com Phone617-830-3031 Debt Debt-to-Equity Ratio0.15 Current Ratio1.61 Quick Ratio1.55 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$860,000.00 Price / Sales114.54 Cash FlowN/A Price / Cash FlowN/A Book Value$1.88 per share Price / Book0.81 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-38,990,000.00 Net Margins-6,345.29% Return on Equity-56.88% Return on Assets-43.93% Miscellaneous Employees103 Outstanding Shares64,380,000Market Cap$90.14 million OptionableOptionable VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions What is VBI Vaccines' stock symbol? VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV." How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc (NASDAQ:VBIV) issued its quarterly earnings results on Friday, November, 9th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. The biopharmaceutical company had revenue of $0.26 million for the quarter, compared to analysts' expectations of $0.24 million. VBI Vaccines had a negative net margin of 6,345.29% and a negative return on equity of 56.88%. View VBI Vaccines' Earnings History. When is VBI Vaccines' next earnings date? VBI Vaccines is scheduled to release their next quarterly earnings announcement on Friday, February 8th 2019. View Earnings Estimates for VBI Vaccines. What price target have analysts set for VBIV? 2 equities research analysts have issued 12-month price objectives for VBI Vaccines' stock. Their forecasts range from $12.00 to $12.00. On average, they anticipate VBI Vaccines' share price to reach $12.00 in the next twelve months. This suggests a possible upside of 684.3% from the stock's current price. View Analyst Price Targets for VBI Vaccines. What is the consensus analysts' recommendation for VBI Vaccines? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for VBI Vaccines. Has VBI Vaccines been receiving favorable news coverage? Headlines about VBIV stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VBI Vaccines earned a news sentiment score of 1.2 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. Who are some of VBI Vaccines' key competitors? Some companies that are related to VBI Vaccines include Five Prime Therapeutics (FPRX), Keryx Biopharmaceuticals (KERX), American Brivision (Holding) (ABVC), Evolus (EOLS), Evelo Biosciences (EVLO), OptiNose (OPTN), Stemline Therapeutics (STML), Concert Pharmaceuticals (CNCE), Aclaris Therapeutics (ACRS), Marker Therapeutics (MRKR), Verastem (VSTM), Minerva Neurosciences (NERV), Aratana Therapeutics (PETX), Albireo Pharma (ALBO) and Avid Bioservices (CDMO). Who are VBI Vaccines' key executives? VBI Vaccines' management team includes the folowing people: Mr. Jeff R. Baxter, CEO, Pres & Director (Age 57)Dr. David Evander Anderson, Chief Scientific Officer (Age 48)Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 63)Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 41)Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 53) Who are VBI Vaccines' major shareholders? VBI Vaccines' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Cambridge Investment Research Advisors Inc. (2.12%) and Renaissance Technologies LLC (0.10%). Company insiders that own VBI Vaccines stock include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc and Steven Gillis. View Institutional Ownership Trends for VBI Vaccines. Which institutional investors are buying VBI Vaccines stock? VBIV stock was bought by a variety of institutional investors in the last quarter, including Cambridge Investment Research Advisors Inc. and Renaissance Technologies LLC. Company insiders that have bought VBI Vaccines stock in the last two years include Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Opko Health, Inc and Steven Gillis. View Insider Buying and Selling for VBI Vaccines. How do I buy shares of VBI Vaccines? Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is VBI Vaccines' stock price today? One share of VBIV stock can currently be purchased for approximately $1.53. How big of a company is VBI Vaccines? VBI Vaccines has a market capitalization of $90.14 million and generates $860,000.00 in revenue each year. VBI Vaccines employs 103 workers across the globe. What is VBI Vaccines' official website? The official website for VBI Vaccines is http://www.vbivaccines.com. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected] MarketBeat Community Rating for VBI Vaccines (NASDAQ VBIV)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 189 (Vote Outperform)Underperform Votes: 161 (Vote Underperform)Total Votes: 350MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote "Outperform" if you believe VBIV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/15/2018 by MarketBeat.com StaffFeatured Article: What is a Roth IRA?